Mesoblast Limited (MESO) News
Track canonical SquawkNews coverage tagged to MESO, Mesoblast Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
MESO - Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
MESO - Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
REGULATION | Sep 24, 2026, 11:00 AM UTC
M
Mesoblast reports revenue growth to US$120M
Mesoblast reported substantial revenue growth to US$120M.
EQUITY | Aug 27, 2026, 12:32 AM UTC
L
MESO - Mesoblast Financial Results and Corporate Update Webcast
MESO - Mesoblast Financial Results and Corporate Update Webcast
EQUITY | Aug 24, 2026, 11:00 AM UTC
L
Mesoblast completes dosing in Phase 3 back pain trial
Mesoblast Limited says it has concluded patient dosing for its Phase 3 MSB-DR004 trial of rexlemestrocel-L in chronic low back pain linked to inflammatory degenerative disc disease.
EARNINGS | Aug 17, 2026, 05:45 PM UTC
H
Mesoblast (MESO) completes patient treatment in pivotal Phase 3
Mesoblast (MESO) says it has achieved a major milestone by completing patient treatment in its pivotal Phase 3 trial for chronic low back pain.
EQUITY | Aug 17, 2026, 12:35 AM UTC
H
Mesoblast: Ryoncil Net Revenues $36M
Mesoblast reports Ryoncil revenues
EQUITY | Jul 30, 2026, 12:57 AM UTC
H
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Wednesday. Shares of PayPal Holdings Inc (NASDAQ: PYPL ) rose sharply following a report that Stripe and Advent International have proposed a
RATES | Jul 15, 2026, 01:56 PM UTC
H
Earnings Flash (MESO) Mesoblast Limited Reports Q4 Revenue $36.0M, vs. FactSet Est of $36.9M
() -- Copyright © 2026. All rights reserved. does not provide investment advice. Unauthorized reproduction is strictly prohibited.
EARNINGS | Jul 10, 2026, 08:23 AM UTC
L
Reported Earlier, Mesoblast Secures BLA Filing Number For Rexlemestrocel-L, Backed By Orphan Drug And RMAT Designations For Priority Review
Reported Earlier, Mesoblast Secures BLA Filing Number For Rexlemestrocel-L, Backed By Orphan Drug And RMAT Designations For Priority Review Eligibility
EQUITY | Jul 01, 2026, 07:34 AM UTC